Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1)
- Target
- KK-LC-1
- Molecular classification
- Cancer/Testis Antigen (CTA)
01
Overview
Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1), also known as CT83 or CXorf61, is a cancer/testis antigen (CTA) with restricted expression in normal tissues (primarily testis) but aberrant expression in various cancers. It promotes tumor proliferation, invasion, and migration, and modulates immune responses. KK-LC-1 serves as a potential biomarker for diagnosis and prognosis, and a promising target for cancer immunotherapy, including TCR-T therapy.
- Other names
- CT83CXorf61
02
Mechanism of action
TCR-T therapy directed against KK-LC-1
03
Biological functions
Tumor promotionNotch1 signaling pathway activationImmune response modulationCell proliferationCell migrationCell invasion
04
Disease associations
CancerLung CancerGastric CancerBreast CancerHepatocellular Carcinoma
05
Safety considerations
Potential off-target effects due to expression in testisImmune-related adverse events associated with immunotherapy
06
Biomarkers
Diagnostic marker for lung adenocarcinomaPrognostic indicator for lung adenocarcinoma and hepatocellular carcinomaCorrelation with TNM stage in lung cancerCorrelation with NSE levels in lung cancerCorrelation with CEA levels in lung cancerTumor Mutation Burden (TMB)KRAS mutation statusALK mutation statusRET mutation statusROS1 mutation statusCD4+ T cell infiltrationMacrophage infiltrationDendritic cell infiltration
Beyond the preview
Go deeper on Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1).